EBS vs PFE · rev $1.04B vs P/E 20, rev $62.58B
Emergent Biosolutions Inc (EBS) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
EBS currently screens at market cap $416.4M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the EBS and PFE stock pages for the full models.
Not investment advice.